# Study of LY2835219 for Mantle Cell Lymphoma

> **NCT01739309** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 28 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT01739309
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-20
- **Primary completion:** 2015-09-28
- **Final completion:** 2022-09-05
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01739309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01739309, "Study of LY2835219 for Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01739309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*